PsiOxus Therapeutics Announces First-in-Human Dosing of their Second Gene Therapy Cancer Treatment.

March 13, 2019 – OXFORD, UK – PsiOxus Therapeutics Ltd. (PsiOxus), the gene therapy for cancer company, today announced that it has started dosing NG-350A, an antibody based cancer gene therapy, to cancer patients. The Phase 1 FORTITUDE study is being conducted at multiple cancer centers in the United States and will assess the safety, tolerability and preliminary anti-tumor activity of NG-350A in subjects with solid tumors.

Download Press Release